Lilly invests $2.1bn in new Indiana manufacturing sites

By Rachel Arthur

- Last updated on GMT

Pic:getty/omersukrugoksu
Pic:getty/omersukrugoksu

Related tags Lilly Eli lilly and company Us Manufacturing

Eli Lilly and Company plans to expand its manufacturing footprint in Indiana by investing $2.1bn in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.

These new facilities will expand Lilly's manufacturing network for active ingredients and new therapeutic modalities, such as genetic medicines.

The investment comes on the back of Lilly’s 2019 expansion in Indiana, which totaled more than $2.5bn over five years and brought the current number of manufacturing employees in Indiana to more than 3,700.

The new project is expected to create up to 500 new Lilly roles with an additional four indirect jobs for every Lilly position created, says Lilly, basing its estimates on industry data. An estimated 1,500 construction jobs will be required while the facilities are being built.

"More than 146 years after our founding, Lilly remains committed to investing and innovating in Indiana," ​said David A. Ricks, Lilly chair and CEO. "These new sites will add capacity in support of our growing pipeline of innovative medicines, while also creating more high-tech jobs for Hoosiers. We are pleased to be a founding investor at the LEAP Lebanon Innovation District."

Over the past eight years, Lilly has delivered 17 new medicines, including tirzepatide (approved by the FDA as Mounjaro) for the treatment of type 2 diabetes, and aims to introduce four potential new medicines in the next two years. These new sites will be ready to support increased demand for existing Lilly products.

The investment in Boone County is contingent upon local zoning and annexation approvals. Lilly is partnering with several organizations throughout the project, including the Indiana Economic Development Corporation.

Related news

Related products

show more

Designing an Optimal APAC Clinical Supply Chain

Designing an Optimal APAC Clinical Supply Chain

Catalent | 08-Mar-2023 | Infographic

With clinical study activity increasing across the Asia-Pacific region, it is important for sponsors—both in APAC and globally—to understand the broader...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Thermo Fisher Scientific - Process Liquid Preparation Services | 21-Feb-2023 | Technical / White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Enhance your cGMP chemical supply chain

Enhance your cGMP chemical supply chain

Thermo Fisher Scientific – Production Chemicals and Services | 09-Feb-2023 | Technical / White Paper

Supply chain issues have real, quantifiable impacts on biomanufacturers. However, the right support can make a cGMP supply chain operate seamlessly. Thermo...

Related suppliers

Follow us

Products

View more

Webinars